The Combination of Rituximab and Bendamustine as First-Line Treatment Is Highly Effective in the Eradicating Minimal Residual Disease in Follicular Lymphoma: An Italian Retrospective Study

• Κύριοι συγγραφείς: Sara Galimberti (Συγγραφέας), Elena Ciabatti (Συγγραφέας), Giacomo Ercolano (Συγγραφέας), Susanna Grassi (Συγγραφέας), Francesca Guerrini (Συγγραφέας), Nadia Cecconi (Συγγραφέας), Martina Rousseau (Συγγραφέας), Giulia Cervetti (Συγγραφέας), Francesco Mazziotta (Συγγραφέας), Lorenzo Iovino (Συγγραφέας), Franca Falzetti (Συγγραφέας), Flavio Falcinelli (Συγγραφέας), Alberto Bosi (Συγγραφέας), Luigi Rigacci (Συγγραφέας), Sofia Kovalchuk (Συγγραφέας), Daniele Vallisa (Συγγραφέας), Lucia Macchia (Συγγραφέας), Eugenio Ciancia (Συγγραφέας), Mario Petrini (Συγγραφέας)
• Μορφή: Βιβλίο
• Έκδοση: Frontiers Media S.A., 2017-06-01T00:00:00Z.
• Θέματα: article
• Διαθέσιμο Online: Connect to this object online.

R-Bendamustine is an effective treatment for follicular lymphoma (FL). Previous large trials demonstrated the prognostic role of the molecular minimal residual disease (MRD) during the most frequently adopted chemotherapeutic regimens, but there are not yet conclusive data about the effect of combin...